Evaluation of the efficacy and safety of L-carnitine in improving liver function in liver injury

Phase 3

Recruiting

• Conditions: Diseases of liver.; Liver disease, unspecified; K76.9

• Registration Number: IRCT20080901001165N69
• Lead Sponsor: Bonyan Salamat Kasra pharmaceutical company

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 November 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Have read and signed a written informed consent to participate in the study
Age between 18-90 years old;
The patient's Child-Pugh score is category B or C;

Exclusion Criteria

Pregnancy;
Breastfeeding;
Participate in another clinical trial at the same time;
History of previous allergies to any of the components of the drug;

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
AST serum level. Timepoint: Before and after intervention. Method of measurement: Blood sample.;ALT serum level. Timepoint: Before and after intervention. Method of measurement: Blood sample.

Secondary Outcome Measures

Name	Time	Method
Bilirubin serum level. Timepoint: Before and after the intervention. Method of measurement: Blood sample.;Child-Pugh score. Timepoint: Before and after the intervention. Method of measurement: Child-Pugh score classification.